Risk stratification and selection for statin therapy: going beyond Framingham

Area of Science:

• Cardiology
• Preventive Medicine
• Medical Decision Making

Background:

• Statin therapy decisions for primary prevention of atherosclerotic cardiovascular disease (ASCVD) often rely on the 10-year Framingham Risk Score (FRS).
• Ambiguity exists for patients with a 10-year FRS of 5%-19% and low-density lipoprotein cholesterol <3.5 mmol/L, even with family history considered.
• Current guidelines suggest using additional factors, but their efficient integration can be complex.

Purpose of the Study:

• To provide a practical framework for refining ASCVD risk assessment beyond the standard FRS.
• To aid clinicians in identifying patients who may benefit from statin therapy despite a seemingly low calculated risk.
• To address the ambiguity in current dyslipidemia guideline recommendations for intermediate-risk patients.

Main Methods:

• Review and synthesis of clinical information, basic biochemical tests, and advanced imaging modalities.
• Integration of data from carotid ultrasound and coronary artery calcium (CAC) scoring.
• Development of a practical approach to risk stratification for primary ASCVD prevention.

Main Results:

• The proposed approach helps identify patients at greater ASCVD risk than indicated by FRS alone.
• Carotid ultrasound and CAC scoring can reveal subclinical atherosclerosis not captured by traditional risk factors.
• This method offers a more nuanced risk assessment for intermediate-risk individuals.

Conclusions:

• A practical approach integrating clinical, biochemical, and imaging data improves ASCVD risk stratification for primary prevention.
• Specialized tests like carotid ultrasound and CAC scoring are valuable in identifying high-risk individuals missed by FRS.
• This strategy can lead to more informed and potentially prudent statin therapy decisions.